Ovarian cancer stem cells and targeted therapy.

Autor: Keyvani V; Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.; Department of Biology, Faculty of Science, Shahid Chamran University of Ahvaz, Ahvaz, Iran., Farshchian M; Stem Cell and Regenerative Medicine Research Group, Academic Center for Education, Culture and Research (ACECR), Khorasan Razavi Branch, Mashhad, Iran., Esmaeili SA; Immunology Research Center, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.; Department of Immunology, Faculty of Medicine, Mashhad University of Medical Science, Mashhad, Iran., Yari H; Human Genetics Division, Medical Biotechnology Department, National Institute of Genetics Engineering and Biotechnology, Tehran, Iran., Moghbeli M; Department of Biology, Faculty of Science, Shahid Chamran University of Ahvaz, Ahvaz, Iran., Nezhad SK; Department of Biology, Faculty of Science, Shahid Chamran University of Ahvaz, Ahvaz, Iran. kazemi_reza@yahoo.de., Abbaszadegan MR; Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Abbaszadeganmr@mums.ac.ir.
Jazyk: angličtina
Zdroj: Journal of ovarian research [J Ovarian Res] 2019 Dec 06; Vol. 12 (1), pp. 120. Date of Electronic Publication: 2019 Dec 06.
DOI: 10.1186/s13048-019-0588-z
Abstrakt: Background: Ovarian cancer has the highest ratio of mortality among gynecologic malignancies. Chemotherapy is one of the most common treatment options for ovarian cancer. However, tumor relapse in patients with advanced tumor stage is still a therapeutic challenge for its clinical management.
Main Body: Therefore, it is required to clarify the molecular biology and mechanisms which are involved in chemo resistance to improve the survival rate of ovarian cancer patients. Cancer stem cells (CSCs) are a sub population of tumor cells which are related to drug resistance and tumor relapse.
Conclusion: In the present review, we summarized the recent findings about the role of CSCs in tumor relapse and drug resistance among ovarian cancer patients. Moreover, we focused on the targeted and combinational therapeutic methods against the ovarian CSCs.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje